Morbi et tellus imperdiet, aliquam nulla sed, dapibus erat. Aenean dapibus sem non purus venenatis vulputate. Donec accumsan eleifend blandit. Nullam auctor ligula

Get In Touch

Quick Email
info.help@gmail.com
  • Home |
  • Merck KGaA drops pipeline assets from SpringWorks buyout, Hengrui licensing deal

Merck KGaA drops pipeline assets from SpringWorks buyout, Hengrui licensing deal

  • March 5, 2026

Merck KGaA is no longer pursuing clinical-stage candidates obtained through its $3.9 billion acquisition of SpringWorks, which centered on approved drugs.

Leave A Comment

Fields (*) Mark are Required